Cornerstone Re-acquires HMGB1 Technology Platform From MedImmune
HMGB1 is a nuclear DNA-binding protein, which is elevated in the body following infection or trauma and may be an important factor when developing therapeutics to treat these
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
Peter Schulz-Knappe, CSO and executive vice president of diagnostics at Protagen, said: “Also classical infectious disease diagnostics can benefit from UNIarray, the proprietary technology platform of Protagen for